3 Jan

Natural Gas ETFs to Watch in 2018

WRITTEN BY Rabindra Samanta

Natural gas ETFs

On December 22–29, the United States Natural Gas Fund (UNG), which holds natural gas futures, rose 11%. UNG’s rise was 10 basis points less than the rise in natural gas February futures during this period.

Natural Gas ETFs to Watch in 2018

During this period, the ProShares Ultra Bloomberg Natural Gas ETF (BOIL) rose 21.3%. Its objective was to match twice the daily changes of the Bloomberg Natural Gas Subindex. So, BOIL might be the best bet for any possible upside in natural gas prices in 2018.

March 2016

Between March 3, 2016, and December 29, 2017, natural gas active futures rose 80.2%. Natural gas (GASL) (FCG) (GASX) active futures closed at $1.64 per MMBtu on March 3, 2016—the lowest closing price in 17 years. UNG rose 0.7%, while BOIL fell 26.5% from this date.

The difference in ETFs’ returns compared to natural gas might have been due to active futures trading less than next month’s futures or the negative roll yield.

On December 29, 2017, the closing prices of natural gas futures contracts between March 2018 and May 2018 were progressively lower. It might help these ETFs gain more.

In BOIL’s case, the actual and expected returns could be different due to daily price changes.

Latest articles

On November 14, The George Soros Fund Management LLC filed 13F. The firm's total market value was around $3.6 billion at the end of Q3 2019.

Tesla (TSLA) stock short sellers seem to be getting exasperated. Notably, Tesla stock has been the short sellers’ favorite.

In the week that ended on November 15, natural gas prices fell 3.5% and settled at 2.688 per MMBtu (million British thermal units).

The Dow Jones Index (DIA) and S&P 500 (SPY) are trading at record highs and on Friday the Dow Jones crossed the 28,000 level for the first time.

Goldman Sachs (GS) settled a lawsuit that alleged it rigged bond prices. Also, Deutsche Bank agreed to pay a fine of $15 million to settle a lawsuit.

In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.